# Giovanni Battista Migliori

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/giovanni-battista-migliori/

## Facts

| Field | Value |
| --- | --- |
| Citations | 39,151 |
| Field | Tuberculosis Research and Epidemiology |
| h-index | 97 |
| i10-index | 438 |
| Last Known Institution | Istituti Clinici Scientifici Maugeri |
| OpenAlex ID | https://openalex.org/A5057408967 |
| ORCID iD | https://orcid.org/0000-0002-2597-574X |
| Works | 800 |

## Researcher papers

Showing 12 of 15.

- [Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis](https://scholariq.org/papers/official-american-thoracic-society-centers-for-disease-control-and-prevention/)
- [A living WHO guideline on drugs for covid-19 (2020-2023)](https://scholariq.org/papers/a-living-who-guideline-on-drugs-for-covid-19-2020-2023/)
- [Towards tuberculosis elimination: an action framework for low-incidence countries](https://scholariq.org/papers/towards-tuberculosis-elimination-an-action-framework-for-low-incidence-countries/)
- [Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis](https://scholariq.org/papers/treatment-correlates-of-successful-outcomes-in-pulmonary-multidrug-resistant/)
- [Management of latent<i>Mycobacterium tuberculosis</i>infection: WHO guidelines for low tuberculosis burden countries](https://scholariq.org/papers/management-of-latent-i-mycobacterium-tuberculosis-i-infection-who-guidelines-for/)
- [Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis](https://scholariq.org/papers/best-drug-treatment-for-multidrug-resistant-and-extensively-drug-resistant/)
- [Interferon-γ release assays for the diagnosis of active tuberculosis: a systematic review and meta-analysis](https://scholariq.org/papers/interferon-release-assays-for-the-diagnosis-of-active-tuberculosis-a-systematic/)
- [Multidrug Resistant Pulmonary Tuberculosis Treatment Regimens and Patient Outcomes: An Individual Patient Data Meta-analysis of 9,153 Patients](https://scholariq.org/papers/multidrug-resistant-pulmonary-tuberculosis-treatment-regimens-and-patient/)
- [The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement](https://scholariq.org/papers/the-risk-of-tuberculosis-related-to-tumour-necrosis-factor-antagonist-therapies/)
- [Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline](https://scholariq.org/papers/treatment-of-drug-resistant-tuberculosis-an-official-ats-cdc-ers-idsa-clinical/)
- [Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR- and XDR-TB: a multicentre study](https://scholariq.org/papers/effectiveness-and-safety-of-bedaquiline-containing-regimens-in-the-treatment-of/)
- [MDR/XDR-TB management of patients and contacts: Challenges facing the new decade. The 2020 clinical update by the Global Tuberculosis Network](https://scholariq.org/papers/mdr-xdr-tb-management-of-patients-and-contacts-challenges-facing-the-new-decade/)

## Researcher topics

- [Tuberculosis Research and Epidemiology](https://scholariq.org/topics/tuberculosis-research-and-epidemiology-2/)
- [Diagnosis and treatment of tuberculosis](https://scholariq.org/topics/diagnosis-and-treatment-of-tuberculosis/)
- [Infectious Diseases and Tuberculosis](https://scholariq.org/topics/infectious-diseases-and-tuberculosis/)
- [Pneumocystis jirovecii pneumonia detection and treatment](https://scholariq.org/topics/pneumocystis-jirovecii-pneumonia-detection-and-treatment/)
- [Pneumonia and Respiratory Infections](https://scholariq.org/topics/pneumonia-and-respiratory-infections/)

## Researcher university

- [Istituti Clinici Scientifici Maugeri](https://scholariq.org/institutions/istituti-clinici-scientifici-maugeri/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.